We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Other disorders of the skin and subcutaneous tissue
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
In 2002 a panel representing Contact Dermatology/Photobiology and Photophysics met (on behalf of the European
Society of Contact Dermatitis (ESCD) and the European Society of Photodermatology (ESPD)) to discuss the method
of photopatch testing, a list of recommended agents and interpretation of guidelines for photopatch testing. They
concluded that the differences in photopatch testing methodology which exists within Europe, not only sends out a
confusing message to potential users of this technique, but also makes it quite difficult to compare published data
between studies. Since then a further multicentre photopatch test study has been completed (2011) and the taskforce
recommended a list of photoallergens that should form part of the baseline series for photopatch testing in Europe.
Our group met to discuss how best to produce a consensus statement on methodology as this has not yet formally
been addressed. The time at which the patch tests are removed and subsequently irradiated with UVA, varies across
Europe and it is important to know whether this impacts on photopatch test outcomes. We aim to recruit 252 patients
from 13 centres across Europe who are attending for the investigation of photopatch testing. The aims will be to
determine the pattern and prevalence of photoallergens, whether using a 24 h or 48 h allergen application time
influences photopatch test outcomes and whether a delayed 7 day reading adds value to interpretation of photopatch
test results. The study will have a lead Dermatologist with an interest in Contact dermatitis or Photobiology at each
centre. The methodology used will be the same in all centres.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Interventional type: Drug;
You can take part if:
You may not be able to take part if:
1. Unable to understand and comply with the restrictions and requirements of the study 2. Not able to provide written informed consent 3. Recent sunburn/tan on back within 4 weeks of the planned photopatch testing 4. Systemic immunosuppressants, including oral corticosteroids (>10mg/daily prednisolone) 5. Active skin disease on back precluding testing 6. Potent topical corticosteroid use to back within 5 days of planned recruitment and testing 7. Pregnancy or breastfeeding
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by TAYSIDE and funded by EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 36152
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
